

SUPPLEMENTARY MATERIAL

Supplemental Table S1.

Baseline characteristics	All Patients (N=393) N (%)	AF ablation patients (N=174)	Aflutter Ablation (N=146)	Cardioversion (N=73)	P-value
Mean age, years (\pm SD)	65 (56-72)	63 (53-69)	69 (62-76)	65.5 (57-71)	0.0009
<65	183 (46.5)	100 (57.5)	47 (32.2)	36 (48.7)	<0.001
65-75	138 (35.0)	56 (32.2)	55 (37.7)	37 (36.5)	0.57
\geq 75	73 (18.5)	18 (10.3)	44 (30.1)	11 (14.9)	<0.001
Female	103 (26.1)	46 (26.4)	36 (24.7)	21 (28.4)	0.83
Hypertension [N=382]	172 (45.6)	66 (39.3)	73 (52.9)	33 (46.5)	0.06
Diabetes [N=381]	85 (22.6)	29 (17.3)	34 (24.6)	22 (31.4)	0.05
Cerebrovascular accident / transient ischemic attack [N=380]	34 (9.1)	16 (9.6)	7 (5.1)	11 (15.7)	0.04
Heart Failure [N=381]	131 (34.8)	43 (25.6)	50 (36.2)	38 (54.3)	<0.001
Vascular Disease [N=380]	89 (23.7)	32 (19.1)	41 (29.7)	16 (22.9)	0.09
Valvular Disease	59 (20.3)	20 (14.8)	24 (25.3)	15 (25.0)	0.09
CHADS ₂	1 (0-2)	1 (0-2)	1 (0-2)	2 (1-3)	0.70
CHA ₂ DS ₂ -VASc score	2 (1-3)	2 (0-3)	2.5 (1-4)	2.5 (1-4)	0.78
0	61 (15.5)	45 (25.9)	11 (7.5)	5 (6.8)	<0.001
1	87 (22.1)	38 (21.8)	31 (21.2)	18 (24.3)	0.87
2	76 (19.3)	31 (17.8)	31 (21.2)	14 (18.9)	0.74
3	72 (18.3)	32 (18.4)	25 (17.1)	15 (20.3)	0.85
\geq 4	97 (24.7)	28 (16.1)	48 (32.9)	22 (29.7)	0.001
Left ventricular ejection fraction (N=295)	58 (43-60)	60 (50-63)	56.5 (35-60)	55 (38-60)	0.67
Labs					
Hemoglobin (N=320)	136 (124-147)	139 (130-151)	132 (118-142)	134 (124-145)	0.06
Creatinine (N=328)	86 (73-99.5)	84 (72-96)	91 (72-116)	86 (78-100)	0.18
International normalized ratio (INR) (N=110)*	1.2 (1.1-1.8)	1.1 (1.0-1.4)	1.1 (1.1-2.0)	1.3 (1.1-2.4)	0.20

Anticoagulation/ Antiplatelets					
Warfarin	109 (27.7)	39 (22.4)	45 (30.8)	25 (33.8)	0.11
Direct oral anticoagulants	233 (61.4)	107 (64.1)	84 (59.6)	42 (60.0)	0.69
Apixaban	85 (21.6)	38 (21.8)	30 (20.6)	17 (23.0)	0.91
Low Dose	2 (0.5)	1 (0.6)	1 (0.7)	0 (0.0)	0.79
High Dose	83 (21.1)	37 (21.3)	29 (19.9)	17 (23.0)	0.86
Dabigatran	58 (15.3)	31 (18.6)	19 (13.5)	8 (11.4)	0.28
Low Dose	8 (2.0)	3 (1.7)	4 (2.7)	1 (1.4)	0.73
High Dose	50 (13.2)	28 (16.8)	15 (10.6)	7 (10.0)	0.19
Rivaroxaban	90 (22.8)	38 (21.8)	35 (24.0)	17 (23.0)	0.90
Low Dose	4 (1.0)	0 (0.0)	4 (2.7)	0 (0.0)	0.03
High Dose	86 (21.8)	38 (21.8)	31 (21.3)	17 (23.0)	0.96
Antiplatelet Agents	35 (9.3)	21 (12.6)	11 (7.8)	3 (4.3)	0.10
None	17 (4.3)	7 (4.0)	6 (4.1)	4 (5.4)	0.88
LAA thrombus	43 (10.9)	16 (9.2)	15 (10.3)	12 (20.5)	0.29

Supplemental Table S2. Univariate Analysis of predictors of LAA thrombus on TEE.

Covariates	OR	95% CI
Age	1.03	1.01-1.07
Paroxysmal AF	0.47	0.22-0.99
Persistent AF	2.33	1.14- 4.81
Prior Cerebrovascular Accident	3.41	1.47-7.93
Heart Failure	3.59	1.86-6.95
Valvular Disease	6.41	3.09-13.29
CHADS ₂	1.55	1.23-1.95
CHA ₂ DS ₂ -Vasc	1.35	1.14-1.60
Left Atrial Diameter	1.15	1.04-1.28
Left Ventricular Ejection Fraction (LVEF)	0.97	0.95-0.99
International Normalized Ratio (INR)	1.94	1.32-2.84
Warfarin	3.24	1.72-6.10
Direct Oral Anticoagulation (DOAC)	0.30	0.15-0.58

*Covariates displayed in table A2 were all statistically significant. Non-statistically significant covariates were not displayed in table A2.